[Induced pluripotent stem (iPS) cell - issues for clinical application - ].
Induced pluripotent stem (iPS) cells are generated from somatic cells by introducing small sets of transcription factors. iPS cells demonstrate pluripotency and the ability to self-renew. In addition, iPS cells can be generated from donor individuals with particular characteristics. Based on these features, iPS cells are expected to be applicable in drug discovery, the study of disease mechanisms and cell therapy. From a technical point of view, "diversity" is the key word. At present, iPS cells can be derived using various techniques, resulting in diversity in the quality of iPS cells generated. Therefore, optimization of the derivation technology is one of the most important issues. Another "diversity" is in the propensities amongst iPS cell lines derived using similar techniques. Thus, strategies for selecting good quality lines remain to be established. Considering such technical hurdles, establishment of an iPS cell bank consisting of high quality and versatile iPS lines is a promising idea because of the merits of cost and quality control. Now, we are exploring relevant parameters for the quality control of banked cells. The challenges facing clinical application of iPS cells are new but not unprecedented. To realize clinical applications of iPS cells, we need to make these challenges clear and overcome them through partnership not only with industry, governments and universities, but also patients and society at large.
Department of Regulatory Science, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan. takaaoi@cira.kyoto-u.ac.jp
Takashi
T
Aoi
D000818:Animals; D064987:Cell- and Tissue-Based Therapy; D055808:Drug Discovery; D006801:Humans; D039904:Pluripotent Stem Cells; D011786:Quality Control; D014015:Tissue Banks; D014157:Transcription Factors
D014157:Transcription Factors